Although the progesterone receptor is not well-established as a therapeutic target in HGSOC, mifepristone (RU486), a progesterone receptor antagonist, was demonstrated to have a response rate of 26.5% in cisplatin- and paclitaxel-resistant ovarian cancer [37]. This evidence concerns the gene PGR and ovarian cancer.